The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CTOR | +29.59% | N/A | N/A | -87% |
| S&P | +15.66% | +86.6% | +13.29% | +74% |
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $169.53M | 793.7% |
| Net Income | -$4,996.66K | 0.0% |
| EBITDA | -$4,711.51K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.92M | 0.0% |
| Inventory | 22.3 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.80M | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Return On Assets | 3.44% | 0.0% |
| Return On Invested Capital | -26.57% | -5.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5,534.94K | 0.0% |
| Operating Free Cash Flow | -$5,534.94K | 0.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 40.61 | 54.86 | 85.29 | - | |
| Price to Book | 1.78 | 1.61 | 8.73 | 4.48 | -247.38% |
| Price to Tangible Book Value | -2.52 | -2.07 | -8.24 | -3.54 | 16.45% |
| Enterprise Value to EBITDA | -13.46 | -9.42 | -63.71 | -34.85 | -95.01% |
| Return on Equity | 3.5% | - | |||
| Total Debt | $3.80M | $3.80M | $3.80M | $3.80M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
